CoChat

REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Objective: The purpose of this study was to examine the effects of REL-1017 (esmethadone), a novel N-methyl-d-aspartate receptor (NMDAR) channel blocker, in patients with major depressive disorder who failed to benefit from one to three standard antidepressant treatments in their current major depressive episode. Methods: A 7-day phase 2 multicenter randomized double-blind placebo-controlled trial, comprising three arms, was conducted to assess the safety, tolerability, pharmacokinetics, and efficacy of two dosages of REL-1017 (25 mg or 50 mg orally once a day). Patients were randomly assigned in a 1:1:1 ratio to placebo (N=22), REL-1017 25 mg/day (N=19), or REL-1017 50 mg/day (N=21). Safety scales included the 4-item Positive Symptom Rating Scale for psychotomimetic symptoms, the Clinician-Administered Dissociative States Scale for dissociative symptoms, the Clinical Opiate Withdrawal Scale for withdrawal signs and symptoms, and the Columbia-Suicide Severity Rating Scale for suicidality. The primary efficacy endpoint was the Montgomery‐Åsberg Depression Scale (MADRS) score. All 62 randomly assigned patients were included in the full analysis set population analysis. Results: Patients experienced mild or moderate transient adverse events and no evidence of dissociative or psychotomimetic effects, opioid effects, or withdrawal signs and symptoms. The improvement in MADRS score shown on day 4 in both of the REL-1017 dosage groups was sustained through day 7 (last dose) and day 14 (7 days after the last dose), with effect sizes from 0.7 to 1.0. Conclusions: This trial showed favorable safety, tolerability, and pharmacokinetic profiles and suggests that REL-1017 may have rapid and sustained antidepressant effects compared with placebo in patients with inadequate responses to antidepressant treatments. These results will need confirmation in larger and longer trials.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2021.21020197

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 28 · Cited by 83

Research works printed but not linked: 5

  1. Eddy NB, 1957, Bull World Health Organ, 17, 569
  2. Codd EE, 1995, J Pharmacol Exp Ther, 274, 1263
  3. Isbell H, 1948, J Pharmacol Exp Ther, 93, 305
  4. Sheehan DV, 1998, J Clin Psychiatry, 59, 22
  5. Busner J, 2007, Psychiatry (Edgmont), 4, 28

Metadata

Authors
Fava, M., Stahl, S., Pani, L., De Martin, S., Pappagallo, M., Guidetti, C., Alimonti, A., Bettini, E., Mangano, R. M., Wessel, T., de Somer, M., Caron, J., Vitolo, O. V., DiGuglielmo, G. R., Gilbert, A., Mehta, H., Kearney, M., Mattarei, A., Gentilucci, M., Folli, F., Traversa, S., Inturrisi, C. E., & Manfredi, P. L.
Affiliations
  • Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy ...
  • Albert Einstein College of Medicine (US)
Venue
American Journal of Psychiatry
Published
2022-02
Volume
179
Issue
2
Pages
122-131
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W4200195182
Cited by
83
References
28
Citations by year
2026: 7 · 2025: 14 · 2024: 18 · 2023: 22 · 2022: 21
FWCI
9.05
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
  • Padua Research Archive (University of Padova) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
major depressive disorder, NMDA receptor antagonists, adjunctive antidepressant therapy, treatment-resistant depression, antidepressant efficacy, drug safety and tolerability, pharmacokinetics, dissociative symptoms, psychotomimetic effects, opioid withdrawal
MeSH terms
Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Humans, Treatment Outcome, Suicidal Ideation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial. https://app.cochat.ai/papers/10.1176/appi.ajp.2021.21020197
The paper
Fava, M., Stahl, S., Pani, L., De Martin, S., Pappagallo, M., Guidetti, C., Alimonti, A., Bettini, E., Mangano, R. M., Wessel, T., de Somer, M., Caron, J., Vitolo, O. V., DiGuglielmo, G. R., Gilbert, A., Mehta, H., Kearney, M., Mattarei, A., Gentilucci, M., . . . Manfredi, P. L. (2022). REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2021.21020197

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.